Non-Small Cell Lung Cancer (NSCLC) - China Drug Forecast and Industrial Trend and Market Demand Analysis to 2025
"Non-Small Cell Lung Cancer (NSCLC) - China Drug Forecast and Market Analysis to 2025" The Report covers current Industries Trends, Worldwide Analysis, Global Forecast, Review, Share, Size, Growth, Effect. Description- Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident cases, approximately 85% are the non-small cell lung cancer (NSCLC) subtype. NSCLC patients are usually diagnosed in the later stages of the disease, with poor prognosis. Historically, treatment options for advanced-stage NSCLC patients have been dominated by chemotherapy. However, the launch of targeted therapies such as Iressa (gefitinib) in 2003, Tarceva (erlotinib) in 2004, and Xalkori (crizotinib) in 2011, has shifted the treatment landscape towards personalized medicine. Get Sample Report With TOC @ http://www.researchmoz.us/enquiry.php?type=S&repid=915842 In 2015, the NSCLC market in China was an estimat...